News
VNDA
3.840
+0.79%
0.030
Weekly Report: what happened at VNDA last week (1109-1113)?
Weekly Report · 1d ago
Vanda Pharmaceuticals Earnings Call Signals Growth Amid Risks
TipRanks · 2d ago
Corbus Pharmaceuticals Holdings Inc. Stock Sheds 14.8%, Underperforms Peers
Dow Jones · 4d ago
NEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art Week
PR Newswire · 6d ago
Corbus Pharmaceuticals Holdings Inc. Stock Advances 11.6%, Outperforms Peers
Dow Jones · 6d ago
Corbus Pharmaceuticals Holdings Inc. Stock Rises 14.7%, Outperforms Peers
Dow Jones · 11/09 21:33
Weekly Report: what happened at VNDA last week (1102-1106)?
Weekly Report · 11/09 09:13
Corbus Pharmaceuticals Holdings Inc. Stock Rises 7.3%, Outperforms Peers
Dow Jones · 11/06 21:34
Corbus Pharmaceuticals Holdings Inc. Stock Slides 19.9%, Underperforms Peers
Dow Jones · 11/05 21:32
Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
PR Newswire · 11/03 21:30
Corbus Pharmaceuticals Holdings Inc. Stock Sheds 7.2%, Underperforms Peers
Dow Jones · 11/02 21:34
Vanda’s Strong Results and Pipeline Catalysts Support Buy Rating; $20 Price Target Maintained
TipRanks · 11/02 15:26
Weekly Report: what happened at VNDA last week (1026-1030)?
Weekly Report · 11/02 09:13
Analysts Offer Insights on Healthcare Companies: Vanda (VNDA) and Viking Therapeutics (VKTX)
TipRanks · 10/29 13:20
Cantor Fitzgerald Sticks to Their Buy Rating for Vanda (VNDA)
TipRanks · 10/29 12:18
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 10/29 12:05
Vanda Pharmaceuticals Inc. Reports Third Quarter 2026 Financial Results
NASDAQ · 10/29 00:22
Vanda Pharma Q3 2026 Earnings Call Transcript
Benzinga · 10/28 21:54
Vanda Pharmaceuticals GAAP EPS of -$0.37 beats by $0.31, revenue of $69.82M beats by $0.7M
Seeking Alpha · 10/28 20:29
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 10/28 20:20
More
Webull provides a variety of real-time VNDA stock news. You can receive the latest news about Vanda Pharma through multiple platforms. This information may help you make smarter investment decisions.
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company, which is focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.